Innoviva, Inc.
Innoviva, Inc. is a U.S.-based diversified biopharmaceutical company built around two main engines: royalty income from respiratory drugs partnered with GSK and a hospital-focused specialty therapeutics business. It also holds strategic healthcare investments, using capital allocation and acquisitions to expand beyond its legacy royalty model.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueContractual royalties from GSK sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
Hospital-use therapies such as GIAPREZA for shock and XACDURO for severe pneumonia.
Anti-infective products including XERAVA, ZEVTERA and NUZOLVENCE.
Milestones, supply arrangements and other collaboration-related revenue.
Equity stakes, loans and acquired assets that may create future optionality.
Products
Reported · share of revenue- Royalty57.5 %
- Xacduro18.1 %
- Giapreza17.9 %
- Xerava5.7 %
- License and Other Revenue0.7 %
- ZEVTERA0.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Innoviva's royalty customers are ultimately patients treated through GSK's global respiratory franchise, while Innoviva itself receives royalty payments from GSK rather than selling directly to end users. Its operating business sells to hospitals, health systems, distributors and other healthcare purchasing organizations that need acute-care and anti-infective therapies. The company also monetizes value through licensing counterparties and strategic healthcare partners such as Zai Lab and Basilea.
GSK commercializes RELVAR/BREO and ANORO globally and pays Innoviva royalties on sales.
Buy GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE for inpatient care.
Purchase and channel Innoviva products into hospital and institutional settings.
Partners such as Zai Lab support ex-U.S. supply, licensing and market access.
Portfolio companies and funds that receive capital, loans or equity support.
Strategy
Innoviva is focused on maximizing value from its GSK royalty stream while scaling its specialty therapeutics platform in critical care and infectious disease. Management is also using capital allocation, acquisitions and strategic investments to broaden the asset base and reduce dependence on any single product or partner. The strategy is designed to convert royalty cash flows into a more diversified biopharmaceutical portfolio with longer-duration growth options.
Product sales can diversify revenue beyond royalties and improve long-term growth.
Royalty cash flow remains the core economic engine and funds portfolio expansion.
New assets can create optionality and reduce concentration risk.
Geography
Innoviva is headquartered in Burlingame, California and operates as a U.S.-based company with global exposure through GSK's respiratory franchise. Its operating products generate U.S. hospital sales and ex-U.S. sales, while royalty revenue is tied to worldwide sales of partnered respiratory products. The company also has licensing and supply activity linked to China and other international markets through collaboration partners.
Risks
Innoviva remains exposed to concentration in GSK-partnered royalties, so competitive pressure or weaker commercialization of BREO/ANORO can directly reduce cash flow. Its operating business depends on hospital purchasing patterns, product launches and supply execution, while its investment portfolio adds valuation volatility. Like other biopharma companies, it also faces regulatory, patent, manufacturing, cybersecurity and public-health risks that can affect revenue timing and expense levels.
- Dependence on GSK royalty performanceImpact: HighLikelihood: High
A large share of value comes from partnered respiratory products sold by GSK.
Exposure: RELVAR/BREO ELLIPTA and ANORO ELLIPTA
- Competitive pressure in respiratory marketsImpact: HighLikelihood: Medium
Competing therapies can reduce sales of the underlying products and royalty base.
Exposure: Global COPD and asthma markets
- Hospital demand and launch executionImpact: MediumLikelihood: High
Product sales depend on formulary access, adoption and procurement timing.
Exposure - Fair value volatility in strategic investmentsImpact: MediumLikelihood: Low
Equity and fund investments can swing earnings through unrealized gains/losses.
Exposure: Armata and other healthcare investments
- Cybersecurity and data integrityImpact: MediumLikelihood: Low
Multiple IT platforms and third-party systems increase breach and disruption risk.
Exposure: Corporate systems and confidential data
Accounting
Judgemental itemsChargebacks, discounts, returns and rebates reduce reported net revenue.
Impact: Affects GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE sales
Royalty revenue is based on GSK sales and contract tiers, creating timing and estimate risk.
Impact: Impacts BREO/RELVAR and ANORO royalty revenue
Strategic equity and fund holdings are marked to market or fair value.
Impact: Can create large unrealized gains or losses in earnings
Historical milestone fees are amortized over product lives.
Impact: Reduces net royalty revenue each period
Similar listed companies
Publicly listed companies with a comparable business focus.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Last updated: 24/09/2026